24 May 2013
Keywords: bayer, corp, starts, ph, iii, evaluation, trasyol
Article | 18 April 2005
Bayer Pharmaceuticals Corp, the US division of the like-named German group, has initiated a double-blind, placebo-controlled, 360-patient
Phase III clinical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
11 April 2005
18 April 2005
© 2013 thepharmaletter.com